2 stories
The announcement concerns an mRNA neoantigen therapy developed with Merck; commenters welcomed the prospect while noting that company statements are not the same as a published dataset.
The tension is healthy rather than cynical: oncology trials fail often, and a clinical headline needs endpoints, duration, and safety detail before it becomes practice.
The top HN threads: facts from the discussions, both sides, insider voices. Email, Telegram, or RSS.
The vaccine in question is not COVID. It is a seasonal flu shot built on mRNA, which can be reformulated late enough to chase the strains that actually circulate rather than a months-old guess.
The 'agency drama' in the headline traces to Vinay Prasad, an FDA official critics call vaccine-skeptical. The expert committee recommended approval over that internal resistance.
Then the thread turned on the official's defenders, and on the article itself for citing no data.